Logo image of CLYM

CLIMB BIO INC (CLYM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLYM - US28658R1068 - Common Stock

1.84 USD
+0.04 (+2.22%)
Last: 11/26/2025, 8:23:32 PM
1.84 USD
0 (0%)
After Hours: 11/26/2025, 8:23:32 PM
Fundamental Rating

3

Overall CLYM gets a fundamental rating of 3 out of 10. We evaluated CLYM against 533 industry peers in the Biotechnology industry. CLYM has a great financial health rating, but its profitability evaluates not so good. CLYM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLYM had negative earnings in the past year.
In the past year CLYM has reported a negative cash flow from operations.
CLYM had negative earnings in each of the past 5 years.
In the past 5 years CLYM always reported negative operating cash flow.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of CLYM (-27.84%) is better than 69.79% of its industry peers.
CLYM's Return On Equity of -28.67% is fine compared to the rest of the industry. CLYM outperforms 78.42% of its industry peers.
Industry RankSector Rank
ROA -27.84%
ROE -28.67%
ROIC N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLYM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

CLYM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLYM has more shares outstanding
CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CLYM has an Altman-Z score of 11.35. This indicates that CLYM is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.35, CLYM belongs to the top of the industry, outperforming 83.68% of the companies in the same industry.
There is no outstanding debt for CLYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.35
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 18.38 indicates that CLYM has no problem at all paying its short term obligations.
With an excellent Current ratio value of 18.38, CLYM belongs to the best of the industry, outperforming 94.93% of the companies in the same industry.
A Quick Ratio of 18.38 indicates that CLYM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 18.38, CLYM belongs to the top of the industry, outperforming 94.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.38
Quick Ratio 18.38
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

CLYM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.84%, which is quite impressive.
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CLYM will show a small growth in Earnings Per Share. The EPS will grow by 1.24% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.87%
EPS Next 2Y23.94%
EPS Next 3Y11.86%
EPS Next 5Y1.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly Revenue VS EstimatesCLYM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLYM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLYM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.94%
EPS Next 3Y11.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLYM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLIMB BIO INC

NASDAQ:CLYM (11/26/2025, 8:23:32 PM)

After market: 1.84 0 (0%)

1.84

+0.04 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)N/A N/A
Inst Owners81.77%
Inst Owner ChangeN/A
Ins Owners0.52%
Ins Owner Change47.72%
Market Cap125.45M
Revenue(TTM)N/A
Net Income(TTM)-50.75M
Analysts90
Price Target9.38 (409.78%)
Short Float %1.92%
Short Ratio1.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.05%
Min EPS beat(2)-27%
Max EPS beat(2)31.11%
EPS beat(4)2
Avg EPS beat(4)-20.87%
Min EPS beat(4)-102.61%
Max EPS beat(4)31.11%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.22%
PT rev (3m)-8%
EPS NQ rev (1m)-23.87%
EPS NQ rev (3m)1.54%
EPS NY rev (1m)0%
EPS NY rev (3m)17.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS2.6
TBVpS2.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.84%
ROE -28.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.38
Quick Ratio 18.38
Altman-Z 11.35
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.8%
EPS Next Y52.87%
EPS Next 2Y23.94%
EPS Next 3Y11.86%
EPS Next 5Y1.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-149.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.43%
OCF growth 3YN/A
OCF growth 5YN/A

CLIMB BIO INC / CLYM FAQ

What is the fundamental rating for CLYM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLYM.


What is the valuation status for CLYM stock?

ChartMill assigns a valuation rating of 0 / 10 to CLIMB BIO INC (CLYM). This can be considered as Overvalued.


How profitable is CLIMB BIO INC (CLYM) stock?

CLIMB BIO INC (CLYM) has a profitability rating of 1 / 10.


How financially healthy is CLIMB BIO INC?

The financial health rating of CLIMB BIO INC (CLYM) is 8 / 10.